---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019849"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T19:06:41.489095+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio Q1 net loss $25.8M; on track to dose first SCD patient in H2 2022

## Summary
- Net loss $25.8M ($0.48 per share); R&D spend $18.2M, G&A $7.7M.
- Cash, equivalents and investments $352.1M as of March 31, 2022; runway into Q4 2024.
- GPH101 for sickle cell disease received FDA Fast Track Designation; first patient dosing target H2 2022, proof-of-concept data in 2023.
- GPH102 for beta-thalassemia preclinical data presented at ASGCT; IND submission expected by mid-2024.

## SEC filing metadata
- accession: 0001564590-22-019849
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000156459022019849/0001564590-22-019849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000156459022019849/grph-8k_20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019849
- JSON: https://secwatch.observer/filing/0001564590-22-019849.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019849.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.